Hospitalizations in Patients With Atrial Fibrillation: An

Europace

18, 1135-42

DOI: 10.1093/europace/euv404

Citation Report

#	Article	IF	Citations
1	Challenges in Atrial Fibrillation Beyond Stroke Prevention: Keeping Patients Out of the Hospital. Europace, 2016, 18, 1117-8.	8.4	0
2	Pharmacological and Non-Pharmacological Treatments for Stroke Prevention in Patients With Atrial Fibrillation. Advances in Therapy, 2017, 34, 2274-2294.	5.0	9
3	Atrial Fibrillation Symptom Profiles Associated With Healthcare Utilization: A Latent Class Regression Analysis. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 741-749.	1.3	11
4	Pioneering Australia's First Atrial Fibrillation Guidelines. Heart Lung and Circulation, 2018, 27, 1391-1393.	2.2	0
5	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation. Annals of Internal Medicine, 2018, 169, 774-787.	12.9	27
6	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung and Circulation, 2018, 27, 1209-1266.	2.2	295
7	Challenges in Assessing the Incidence of Atrial Fibrillation Hospitalizations. Canadian Journal of Cardiology, 2019, 35, 1291-1293.	3.8	2
8	Risk of Hospital Admissions in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology, 2019, 35, 1332-1343.	3.8	63
9	Hospitalization Affects the Anticoagulation Patterns of Patients With Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2019, 48, 225-232.	2.2	3
10	Reasons for Hospitalization and Risk of Mortality in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Europace, 2019, 21, 1023-1030.	8.4	6
11	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
12	Drivers of Hospitalisation Trends for Non-Valvular Atrial Fibrillation in Western Australia, 2000–2013. International Journal of Cardiology, 2019, 276, 273-277.	3.2	8
13	Impact of Comorbid Conditions on Disease-Specific Quality of Life in Older Men and Women With Atrial Fibrillation. Quality of Life Research, 2020, 29, 3285-3296.	3.8	8
14	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006511.	5.6	8
15	Drivers of Hospitalization in Atrial Fibrillation: A Contemporary Review. Heart Rhythm, 2020, 17, 1991-1999.	3.8	14
16	The Reward of Understanding Risk in Atrial Fibrillation. European Journal of Preventive Cardiology, 2021, 28, 622-623.	6.1	0
17	Oxidized CaMKII and O-GlcNAcylation Cause Increased Atrial Fibrillation in Diabetic Mice by Distinct Mechanisms. Journal of Clinical Investigation, 2021, .	12.9	75
18	Incidence and Predictors of Hospitalization in Patients With Atrial Fibrillation: Results From the Chinese Atrial Fibrillation Registry Study. BMC Cardiovascular Disorders, 2021, 21, 1-10.	3.3	12

#	Article	IF	Citations
19	Determinants of Prolonged Length of Hospital Stay of Patients With Atrial Fibrillation. Journal of Clinical Medicine, 2021, 10, 3715.	3.8	22
20	Atrial Fibrillation Epidemiology, Disparity and Healthcare Contacts: A Population-Wide Study of 5.6 Million Individuals. Lancet Regional Health - Europe, The, 2021, 7, 100157.	13.5	81
21	Association Between Economic and Arrhythmic Burden of Paroxysmal Atrial Fibrillation in Patients With Cardiac Implanted Electronic Devices. American Heart Journal, 2022, 244, 116-124.	3.3	7
22	Catheter Ablation for Atrial Fibrillation Is Associated With Reduced Risk of Mortality in the Elderly: A Prospective Cohort Study and Propensity Score Analysis. Journal of Geriatric Cardiology, 2020, 17, 740-749.	2.7	6
23	Unplanned 30-Day Readmission, Comorbidity, and Impact on Mortality After Incident Atrial Fibrillation Hospitalization in Western Australia, 2001–2015. Heart Rhythm O2, 2022, 3, 511-519.	2.6	8
24	Emergent Readmission and Long-Term Mortality Risk After Incident Atrial Fibrillation Hospitalisation. Heart, 2023, 109, 380-387.	4.9	11
25	The Prognostic Value of Quality of Life in Atrial Fibrillation on Patient Value. Health and Quality of Life Outcomes, 2023, 21, 1-10.	4.1	7
26	Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands. JAMA Network Open, 2023, 6, e239973-e239973.	10.2	20
27	Should Atrial Fibrillation Be Considered a Vascular Disease? The Need for a Comprehensive Vascular Approach. Expert Review of Cardiovascular Therapy, 2023, 21, 779-790.	2.7	6
28	Long-Term Pattern and Associated Costs of Re-Hospitalisations in Patients After Index Atrial Fibrillation Admission in Western Australia, 2011–2017. Heart Lung and Circulation, 2024, 33, 55-64.	2.2	5
29	Direct Oral Anticoagulant Use in Hospitalized Patients With Atrial Fibrillation Across Body Mass Index Categories: Design and Rationale for a Retrospective Cohort Study. Therapeutic Advances in Drug Safety, 2024, 15, 20420986241227014.	3.0	0
30	Incidence of All-Cause, Cardiovascular, and Atrial Fibrillation-Related Hospitalizations: Focus on Antiarrhythmic Drugs. JACC: Advances, 2024, 3, 101117.	3.2	18
31	Adherence to Atrial Fibrillation (AF) Better Care (ABC) Pathway and Adverse Clinical Outcomes in Patients With Atrial Fibrillation. Heliyon, 2025, 11, e43432.	4.8	1